Quick answers
- What is Neomycin sulfate, polymyxin b sulfate and gramicidin used for?
- The FDA-approved label (Neomycin and Polymyxin B Sulfates and Gramicidin, A-S Medication Solutions, February 4, 2026) says: “Neomycin and polymyxin B sulfates and gramicidin ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Neomycin sulfate, polymyxin b sulfate and gramicidin?
- The “Adverse Reactions” section of the FDA label (Neomycin and Polymyxin B Sulfates and Gramicidin, A-S Medication Solutions, February 4, 2026) begins: “Adverse reactions have occurred with the anti-infective components of this product. The exact incidence is not known. Reactions occurring most often are allergic reactions including itching, swelling, and conjunctival erythema (see WARNINGS). More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. Local irritation on instillation has also been reported.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Neomycin sulfate, polymyxin b sulfate and gramicidin have a boxed warning?
- No. None of the 2 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Neomycin sulfate, polymyxin b sulfate and gramicidin?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Neomycin sulfate, polymyxin b sulfate and gramicidin been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Neomycin sulfate, polymyxin b sulfate and gramicidin?
- 2 companies list prescription products of Neomycin sulfate, polymyxin b sulfate and gramicidin in the FDA NDC Directory, including Bausch & Lomb Incorporated and A-S Medication Solutions.
What Neomycin sulfate, polymyxin b sulfate and gramicidin is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Neomycin and polymyxin B sulfates and gramicidin ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.
— FDA label: Neomycin and Polymyxin B Sulfates and Gramicidin, A-S Medication Solutions, effective February 4, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (solution/ drops, ophthalmic), Neomycin and Polymyxin B Sulfates and Gramicidin, A-S Medication Solutions; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 2 FDA labels for this medicine have a boxed warning.
Neomycin sulfate, polymyxin b sulfate and gramicidin side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
Adverse reactions have occurred with the anti-infective components of this product. The exact incidence is not known. Reactions occurring most often are allergic reactions including itching, swelling, and conjunctival erythema (see WARNINGS). More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. Local irritation on instillation has also been reported.
Read more of this section
To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
— FDA label: Neomycin and Polymyxin B Sulfates and Gramicidin, A-S Medication Solutions, effective February 4, 2026. Read the full label on DailyMed →
Neomycin sulfate, polymyxin b sulfate and gramicidin dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Instill one or two drops into the affected eye every 4 hours for 7 to 10 days. In severe infections, dosage may be increased to as much as two drops every hour. donot
— FDA label: Neomycin and Polymyxin B Sulfates and Gramicidin, A-S Medication Solutions, effective February 4, 2026. Read the full label on DailyMed →
Neomycin sulfate, polymyxin b sulfate and gramicidin in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Teratogenic Effects Adequate animal reproductive studies have not been conducted with neomycin, polymyxin B, or gramicidin. It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This product should be given to a pregnant woman only if clearly needed.
— FDA label: Neomycin and Polymyxin B Sulfates and Gramicidin, A-S Medication Solutions, effective February 4, 2026. Read the full label on DailyMed →
Neomycin sulfate, polymyxin b sulfate and gramicidin and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.
— FDA label: Neomycin and Polymyxin B Sulfates and Gramicidin, A-S Medication Solutions, effective February 4, 2026. Read the full label on DailyMed →
When Neomycin sulfate, polymyxin b sulfate and gramicidin should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
This product is contraindicated in those persons who have shown hypersensitivity to any of its components.
— FDA label: Neomycin and Polymyxin B Sulfates and Gramicidin, A-S Medication Solutions, effective February 4, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Solution/ drops |
|---|---|
| Route | Ophthalmic |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Neomycin and Polymyxin B Sulfates and Gramicidin |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| gramicidin 0.025 mg/mL · neomycin sulfate 1.75 mg/mL · polymyxin b sulfate 10000 USP units/mL solution/ drops | Generic | $4.49 per mL |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bausch & Lomb Incorporated1 product
- A-S Medication Solutions1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (1)
- ANDA064047Bausch and Lomb Inc · January 31, 1996
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 310594 |
|---|---|
| SPL set ID of the quoted label | 9691178e-5323-40ce-a8b3-f79e88f02797 |
| FDA labels (SPL) | 2 |
| FDA applications | 1 ANDA |
| Active ingredients (FDA) | GRAMICIDIN / NEOMYCIN / POLYMYXIN B |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Bausch & Lomb IncorporatedMaker or distributor
- A-S Medication SolutionsMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Neomycin and Polymyxin B Sulfates and Gramicidin, A-S Medication Solutions, effective February 4, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →